The €6.7m ($7.1m) series B financing raised by HiberGene will fuel development of the Irish company's R&D pipeline and enable it to add three new infectious disease tests to its Swift rapid molecular diagnostics platform by the end of the year.
To complete this second round of financing, the Dublin-based company tapped several sources of investment. Existing shareholders in the series...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?